Drug
Selgantolimod
Selgantolimod: highest development phase Phase 2, developed by Gilead Sciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Gilead Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| Selgantolimod NCT03615066 | Phase 2 | Chronic Hepatitis B |
Latest
No recent events.
Follow Selgantolimod on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.